AnnMarieMullallyMD

Hematologic Oncology

Associate Professor at Harvard Medical School

Dr. Mullally is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
77 Avenue Louis Pasteur
Harvard Institutes of Medicine Building, Room 738
Boston, MA 02115
Phone+1 617-525-4980

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2010
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
University College of Dublin National Univ SOMClass of 1999

PubMed

1 citations
Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.
Frederike Kramer, Ann Mullally
Journal of Cellular and Molecular Medicine. 2024-03-01
28 citations
Biology and therapeutic targeting of molecular mechanisms in MPNs.
Joan How, Jacqueline S Garcia, Ann Mullally
Blood. 2023-04-20
6 citations
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
Jonas S Jutzi, Anna E Marneth, María José Jiménez-Santos, Jessica Hem, Angel Guerra-Moreno
Leukemia. 2023-02-01

Abstracts/Posters

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response
Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN Pathogenesis
Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model
Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera
Ann Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Friday Scientific Workshop on the Interplay Between Coagulation and Malignancy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/2/2018
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/1/2018
Join now to see all

Harvard Researchers Discover Some Cancers May Originate Decades Earlier Than Previously BelievedMarch 12th, 2021
Original Error: Retracing the History of the Mutation That Gave Rise to Cancer Decades LaterMarch 10th, 2021
Splicing Factor YBX1 Mediates Persistence of JAK2-Mutated NeoplasmsNovember 25th, 2020
Join now to see all